Loading
The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.
Erythropoietin from the kidney binds EPOR on erythroid progenitors and signals through JAK2 and STAT5 to drive red cell production. Recombinant epoetin alfa and darbepoetin alfa raise haemoglobin and reduce transfusions in patients with chemotherapy-induced anaemia, but trials showed shorter survival and more thromboembolism when they were used to target normal haemoglobin levels or given outside chemotherapy, leading to restricted labels and a risk management programme in the United States. They are now used at the lowest dose that avoids transfusion, in patients on palliative-intent chemotherapy.
In plain words · The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.
The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.
Cytokine receptor on erythroid progenitors signalling through JAK2 and STAT5; agonised by recombinant erythropoiesis-stimulating agents.
1 product aims at Erythropoietin receptor (EPOR): other agents. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 3 medicines aimed at it (Epoetin alfa, Darbepoetin alfa, Epoetin theta) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA EPOR: RNA low tissue specificity; no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (myelodysplastic syndrome). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas EPOR tissue; Open Targets ENSG00000187266 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Winkelmann J.C. et al, Blood, 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p". Source.
Cytokine receptor on erythroid progenitors signalling through JAK2 and STAT5; agonised by recombinant erythropoiesis-stimulating agents.
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA EPOR tissue · HPA EPOR pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: erythropoietin receptor on marrow red-cell precursors. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Epoetin theta is a made-to-order version of erythropoietin, the hormone that tells the marrow to make red blood cells. It is used to treat the anaemia of chemotherapy in people with non-myeloid cancers, sparing some transfusions.
Query for this target: (TITLE:"Erythropoietin receptor" OR ABSTRACT:"Erythropoietin receptor" OR TITLE:"EPOR" OR ABSTRACT:"EPOR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Erythropoietin receptor (EPOR), not a curated reading list.
Shares Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22), Epoetin theta.
Shares Epoetin theta, Darbepoetin alfa, Epoetin alfa, Anaemia.
Shares Darbepoetin alfa, Epoetin alfa, Anaemia.
Shares Epoetin alfa, Anaemia, JAK2.